GlassScriptPhysician profile
Bethany Cavan Treibley
NPI 1437890001
$4,180.94
in general payments reported to CMS, 2019-2025
28 companies · $1,507 in 2025
The $1,507 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,586 · 2023: $1,037 · 2024: $50.81 · 2025: $1,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870 · Travel and Lodging: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.37 |
| Travel and Lodging | $724.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,111.78 | 2025 | General - Therapies, Overstitch Endoscopic Suturing System |
| Novo Nordisk INC | $690.00 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $521.55 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $279.40 | 2022-2023 | Farxiga |
| Ardelyx, INC. | $278.74 | 2023 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $198.41 | 2022-2023 | Abilify Maintena, Rexulti |
| Madrigal Pharmaceuticals | $164.92 | 2025 | Rezdiffra |
| Biohaven Pharmaceutical Holding Company LTD. | $130.41 | 2022 | |
| Gilead Sciences, INC. | $91.45 | 2023 | Epclusa |
| Pfizer INC. | $86.02 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $78.70 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $77.19 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $57.46 | 2022-2023 | Xarelto |
| Biogen, INC. | $54.31 | 2022-2023 | Spinraza |
| Merck Sharp & Dohme LLC | $50.15 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $41.20 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.97 | 2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $32.48 | 2022 | |
| Sanofi Pasteur INC. | $31.94 | 2023 | |
| Si-Bone, INC. | $25.59 | 2022 | |
| Amarin Pharma, INC. | $23.33 | 2022 | |
| Exact Sciences Corporation | $21.28 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $18.97 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.68 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.65 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.93 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.68 | 2023 | Xifaxan, Trulance |
| Amgen INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Treibley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.